{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:47:58Z","timestamp":1795085278404,"version":"4.10.2"},"reference-count":172,"publisher":"Bentham Science Publishers Ltd.","issue":"13","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670447"],"award-info":[{"award-number":["81670447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new type of oral hypoglycemic\ndrugs that exert a hypoglycemic effect by blocking the reabsorption of glucose in the proximal\nrenal tubules, thus promoting the excretion of glucose from urine. Their hypoglycemic effect is\nnot dependent on insulin. Increasing data shows that SGLT2 inhibitors improve cardiovascular outcomes\nin patients with type 2 diabetes. Previous studies have demonstrated that SGLT2 inhibitors\ncan reduce pathological myocardial hypertrophy with or without diabetes, but the exact mechanism\nremains to be elucidated. To clarify the relationship between SGLT2 inhibitors and pathological\nmyocardial hypertrophy, with a view to providing a reference for the future treatment thereof, this\nstudy reviewed the possible mechanisms of SGLT2 inhibitors in attenuating pathological myocardial\nhypertrophy. We focused specifically on the mechanisms in terms of inflammation, oxidative\nstress, myocardial fibrosis, mitochondrial function, epicardial lipids, endothelial function, insulin\nresistance, cardiac hydrogen and sodium exchange, and autophagy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450124666230907115831","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:23:21Z","timestamp":1694406201000},"page":"1009-1022","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial\nHypertrophy"],"prefix":"10.2174","volume":"24","author":[{"given":"Zhicheng","family":"Gao","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"},{"name":"Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s\nHospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Bao","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"},{"name":"Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s\nHospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Hu","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"},{"name":"Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s\nHospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Tu","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Ye","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s\nHospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"},{"name":"Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People\u2019s Hospital (Affiliated People\u2019s\nHospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"Scheen A.J.","year":"2015","unstructured":"Scheen A.J.; Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015,75(1),33-59","journal-title":"Drugs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"Abdul-Ghani M.A.","year":"2011","unstructured":"Abdul-Ghani M.A.; Norton L.; DeFronzo R.A.; Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011,32(4),515-531","journal-title":"Endocr Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","volume":"32","author":"Bailey C.J.","year":"2011","unstructured":"Bailey C.J.; Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011,32(2),63-71","journal-title":"Trends Pharmacol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"Roger V.L.","year":"2011","unstructured":"Roger V.L.; Go A.S.; Lloyd-Jones D.M.; Adams R.J.; Berry J.D.; Brown T.M.; Carnethon M.R.; Dai S.; de Simone G.; Ford E.S.; Fox C.S.; Fullerton H.J.; Gillespie C.; Greenlund K.J.; Hailpern S.M.; Heit J.A.; Ho P.M.; Howard V.J.; Kissela B.M.; Kittner S.J.; Lackland D.T.; Lichtman J.H.; Lisabeth L.D.; Makuc D.M.; Marcus G.M.; Marelli A.; Matchar D.B.; McDermott M.M.; Meigs J.B.; Moy C.S.; Mozaffarian D.; Mussolino M.E.; Nichol G.; Paynter N.P.; Rosamond W.D.; Sorlie P.D.; Stafford R.S.; Turan T.N.; Turner M.B.; Wong N.D.; Wylie-Rosett J.; Heart disease and stroke statistics--2011 update: A report from the American Heart Association. Circulation 2011,123(4),e18-e209","journal-title":"Circulation"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"Nakamura M.","year":"2018","unstructured":"Nakamura M.; Sadoshima J.; Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 2018,15(7),387-407","journal-title":"Nat Rev Cardiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","volume":"126","author":"Ritchie R.H.","year":"2020","unstructured":"Ritchie R.H.; Abel E.D.; Basic Mechanisms of Diabetic Heart Disease. Circ Res 2020,126(11),1501-1525","journal-title":"Circ Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.jacc.2013.07.074","volume":"62","author":"Szwejkowski B.R.","year":"2013","unstructured":"Szwejkowski B.R.; Gandy S.J.; Rekhraj S.; Houston J.G.; Lang C.C.; Morris A.D.; George J.; Struthers A.D.; Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol 2013,62(24),2284-2293","journal-title":"J Am Coll Cardiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00125-005-1896-y","volume":"48","author":"Dawson A.","year":"2005","unstructured":"Dawson A.; Morris A.D.; Struthers A.D.; The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005,48(10),1971-1979","journal-title":"Diabetologia"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; de Zeeuw D.; Fulcher G.; Erondu N.; Shaw W.; Law G.; Desai M.; Matthews D.R.; Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Silverman M.G.; Zelniker T.A.; Kuder J.F.; Murphy S.A.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Ruff C.T.; Gause-Nilsson I.A.M.; Fredriksson M.; Johansson P.A.; Langkilde A.M.; Sabatine M.S.; Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","volume":"18","author":"Pabel S.","year":"2021","unstructured":"Pabel S.; Hamdani N.; Luedde M.; Sossalla S.; SGLT2 Inhibitors and Their Mode of Action in Heart Failure\u2014Has the Mystery Been Unravelled? Curr Heart Fail Rep 2021,18(5),315-328","journal-title":"Curr Heart Fail Rep"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"Verma S.","year":"2019","unstructured":"Verma S.; Mazer C.D.; Yan A.T.; Mason T.; Garg V.; Teoh H.; Zuo F.; Quan A.; Farkouh M.E.; Fitchett D.H.; Goodman S.G.; Goldenberg R.M.; Al-Omran M.; Gilbert R.E.; Bhatt D.L.; Leiter L.A.; J&#xFC;ni P.; Zinman B.; Connelly K.A.; Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation 2019,140(21),1693-1702","journal-title":"Circulation"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"Brown A.J.M.","year":"2020","unstructured":"Brown A.J.M.; Gandy S.; McCrimmon R.; Houston J.G.; Struthers A.D.; Lang C.C.; A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: The DAPA-LVH trial. Eur Heart J 2020,41(36),3421-3432","journal-title":"Eur Heart J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"Kusaka H.","year":"2016","unstructured":"Kusaka H.; Koibuchi N.; Hasegawa Y.; Ogawa H.; Kim-Mitsuyama S.; Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 2016,15(1),157","journal-title":"Cardiovasc Diabetol"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320974833","volume":"11","author":"Zhang Q.Q.","year":"2020","unstructured":"Zhang Q.Q.; Li G.Q.; Zhong Y.; Wang J.; Wang A.N.; Zhou X.; Mao X.M.; Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice. Ther Adv Chronic Dis 2020,11","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lfs.2019.05.051","volume":"230","author":"Takasu T.","year":"2019","unstructured":"Takasu T.; Takakura S.; Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sci 2019,230,19-27","journal-title":"Life Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1006\/jmcc.2000.1139","volume":"32","author":"Depre C.","year":"2000","unstructured":"Depre C.; Young M.E.; Ying J.; Ahuja H.S.; Han Q.; Garza N.; Davies P.J.A.; Taegtmeyer H.; Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000,32(6),985-996","journal-title":"J Mol Cell Cardiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/01.RES.87.12.1123","volume":"87","author":"Frustaci A.","year":"2000","unstructured":"Frustaci A.; Kajstura J.; Chimenti C.; Jakoniuk I.; Leri A.; Maseri A.; Nadal-Ginard B.; Anversa P.; Myocardial cell death in human diabetes. Circ Res 2000,87(12),1123-1132","journal-title":"Circ Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"R510","DOI":"10.1152\/ajpregu.00512.2011","volume":"302","author":"Kumar R.","year":"2012","unstructured":"Kumar R.; Yong Q.C.; Thomas C.M.; Baker K.M.; Review: Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol 2012,302(5),R510-R517","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.2337\/db12-1391","volume":"62","author":"Lei S.","year":"2013","unstructured":"Lei S.; Li H.; Xu J.; Liu Y.; Gao X.; Wang J.; Ng K.F.J.; Lau W.B.; Ma X.; Rodrigues B.; Irwin M.G.; Xia Z.; Hyperglycemia-induced protein kinase C &#x3B2;2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt\/eNOS signaling. Diabetes 2013,62(7),2318-2328","journal-title":"Diabetes"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/pgmj.2007.064048","volume":"84","author":"Pappachan J.M.","year":"2008","unstructured":"Pappachan J.M.; Sebastian J.; Bino B.C.; Jayaprakash K.; Vijayakumar K.; Sujathan P.; Adinegara L.A.; Cardiac autonomic neuropathy in diabetes mellitus: Prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis. Postgrad Med J 2008,84(990),205-210","journal-title":"Postgrad Med J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/CIRCULATIONAHA.107.760405","volume":"118","author":"Olshansky B.","year":"2008","unstructured":"Olshansky B.; Sabbah H.N.; Hauptman P.J.; Colucci W.S.; Parasympathetic nervous system and heart failure: Pathophysiology and potential implications for therapy. Circulation 2008,118(8),863-871","journal-title":"Circulation"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1006\/jmcc.2000.1123","volume":"32","author":"Bisognano J.D.","year":"2000","unstructured":"Bisognano J.D.; Weinberger H.D.; Bohlmeyer T.J.; Pende A.; Raynolds M.V.; Sastravaha A.; Roden R.; Asano K.; Blaxall B.C.; Wu S.C.; Communal C.; Singh K.; Colucci W.; Bristow M.R.; Port D.J.; Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000,32(5),817-830","journal-title":"J Mol Cell Cardiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","volume":"1","author":"Tahrani A.A.","year":"2013","unstructured":"Tahrani A.A.; Barnett A.H.; Bailey C.J.; SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013,1(2),140-151","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/01.RES.86.5.494","volume":"86","author":"Griendling K.K.","year":"2000","unstructured":"Griendling K.K.; Sorescu D.; Ushio-Fukai M.; NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000,86(5),494-501","journal-title":"Circ Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","volume":"49","author":"Takimoto E.","year":"2007","unstructured":"Takimoto E.; Kass D.A.; Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007,49(2),241-8","journal-title":"Hypertension"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1097\/01.hjh.0000244956.47114.c1","volume":"24","author":"Yamamoto E.","year":"2006","unstructured":"Yamamoto E.; Lai Z.F.; Yamashita T.; Tanaka T.; Kataoka K.; Tokutomi Y.; Ito T.; Ogawa H.; Kim-Mitsuyama S.; Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006,24(10),2057-2069","journal-title":"J Hypertens"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.vph.2017.06.002","volume":"93-95","author":"Komosa A.","year":"2017","unstructured":"Komosa A.; Rzymski P.; Perek B.; Ropacka-Lesiak M.; Lesiak M.; Siller-Matula J.M.; Poniedzia\u0142ek B.; Platelets redox balance assessment: Current evidence and methodological considerations. Vascul Pharmacol 2017,93-95,6-13","journal-title":"Vascul Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5551\/jat.11114","volume":"19","author":"Takeshima H.","year":"2012","unstructured":"Takeshima H.; Kobayashi N.; Koguchi W.; Ishikawa M.; Sugiyama F.; Ishimitsu T.; Cardioprotective effect of a combination of Rho-kinase inhibitor and p38 MAPK inhibitor on cardiovascular remodeling and oxidative stress in Dahl rats. J Atheroscler Thromb 2012,19(4),326-336","journal-title":"J Atheroscler Thromb"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/00005344-200106000-00010","volume":"37","author":"Tsutsui H.","year":"2001","unstructured":"Tsutsui H.; Ide T.; Hayashidani S.; Kinugawa S.; Suematsu N.; Utsumi H.; Takeshita A.; Effects of ACE inhibition on left ventricular failure and oxidative stress in Dahl salt-sensitive rats. J Cardiovasc Pharmacol 2001,37(6),725-733","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/S0021-9258(18)52251-1","volume":"266","author":"Josephson R.A.","year":"1991","unstructured":"Josephson R.A.; Silverman H.S.; Lakatta E.G.; Stern M.D.; Zweier J.L.; Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. J Biol Chem 1991,266(4),2354-2361","journal-title":"J Biol Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/01.RES.85.2.147","volume":"85","author":"Siwik D.A.","year":"1999","unstructured":"Siwik D.A.; Tzortzis J.D.; Pimental D.R.; Chang D.L.F.; Pagano P.J.; Singh K.; Sawyer D.B.; Colucci W.S.; Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 1999,85(2),147-153","journal-title":"Circ Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/9237263","volume":"2017","author":"Satta S.","year":"2017","unstructured":"Satta S.; Mahmoud A.M.; Wilkinson F.L.; Yvonne Alexander M.; White S.J.; The Role of Nrf2 in Cardiovascular Function and Disease. Oxid Med Cell Longev 2017,2017,1-18","journal-title":"Oxid Med Cell Longev"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"Li C.","year":"2019","unstructured":"Li C.; Zhang J.; Xue M.; Li X.; Han F.; Liu X.; Xu L.; Lu Y.; Cheng Y.; Li T.; Yu X.; Sun B.; Chen L.; SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 2019,18(1),15","journal-title":"Cardiovasc Diabetol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"Herzig S.","year":"2018","unstructured":"Herzig S.; Shaw R.J.; AMPK: Guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol 2018,19(2),121-135","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"Kolijn D.","year":"2021","unstructured":"Kolijn D.; Pabel S.; Tian Y.; L&#xF3;di M.; Herwig M.; Carrizzo A.; Zhazykbayeva S.; Kov&#xE1;cs &#xC1;.; F&#xFC;l&#xF6;p G.&#xC1;.; Falc&#xE3;o-Pires I.; Reusch P.H.; Linthout S.V.; Papp Z.; van Heerebeek L.; Vecchione C.; Maier L.S.; Ciccarelli M.; Tsch&#xF6;pe C.; M&#xFC;gge A.; Bagi Z.; Sossalla S.; Hamdani N.; Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G&#x3B1; oxidation. Cardiovasc Res 2021,117(2),495-507","journal-title":"Cardiovasc Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13578-021-00547-y","volume":"11","author":"Tsai K.L.","year":"2021","unstructured":"Tsai K.L.; Hsieh P.L.; Chou W.C.; Cheng H.C.; Huang Y.T.; Chan S.H.; Dapagliflozin attenuates hypoxia\/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. Cell Biosci 2021,11(1),44","journal-title":"Cell Biosci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"14311","DOI":"10.3390\/ijms131114311","volume":"13","author":"Kong S.S.","year":"2012","unstructured":"Kong S.S.; Liu J.J.; Yu X.J.; Lu Y.; Zang W.J.; Protection against ischemia-induced oxidative stress conferred by vagal stimulation in the rat heart: Involvement of the AMPK-PKC pathway. Int J Mol Sci 2012,13(12),14311-14325","journal-title":"Int J Mol Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"Yurista S.R.","year":"2019","unstructured":"Yurista S.R.; Sillj&#xE9; H.H.W.; Oberdorf-Maass S.U.; Schouten E.M.; Pavez Giani M.G.; Hillebrands J.L.; van Goor H.; van Veldhuisen D.J.; de Boer R.A.; Westenbrink B.D.; Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2019,21(7),862-873","journal-title":"Eur J Heart Fail"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/10590500902885684","volume":"27","author":"Valavanidis A.","year":"2009","unstructured":"Valavanidis A.; Vlachogianni T.; Fiotakis C.; 8-hydroxy-2\u2032 -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 2009,27(2),120-139","journal-title":"J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41514-017-0012-0","volume":"3","author":"Sugizaki T.","year":"2017","unstructured":"Sugizaki T.; Zhu S.; Guo G.; Matsumoto A.; Zhao J.; Endo M.; Horiguchi H.; Morinaga J.; Tian Z.; Kadomatsu T.; Miyata K.; Itoh H.; Oike Y.; Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. NPJ Aging Mech Dis 2017,3(1),12","journal-title":"NPJ Aging Mech Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCULATIONAHA.112.001357","volume":"128","author":"Heymans S.","year":"2013","unstructured":"Heymans S.; Corsten M.F.; Verhesen W.; Carai P.; van Leeuwen R.E.W.; Custers K.; Peters T.; Hazebroek M.; St&#xF6;ger L.; Wijnands E.; Janssen B.J.; Creemers E.E.; Pinto Y.M.; Grimm D.; Sch&#xFC;rmann N.; Vigorito E.; Thum T.; Stassen F.; Yin X.; Mayr M.; de Windt L.J.; Lutgens E.; Wouters K.; de Winther M.P.J.; Zacchigna S.; Giacca M.; van Bilsen M.; Papageorgiou A.P.; Schroen B.; Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013,128(13),1420-1432","journal-title":"Circulation"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2007.09.007","volume":"40","author":"Burkly L.C.","year":"2007","unstructured":"Burkly L.C.; Michaelson J.S.; Hahm K.; Jakubowski A.; Zheng T.S.; TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK\/Fn14 pathway in health and disease. Cytokine 2007,40(1),1-16","journal-title":"Cytokine"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10557-021-07190-2","volume":"36","author":"Yerra V.G.","year":"2022","unstructured":"Yerra V.G.; Batchu S.N.; Kabir G.; Advani S.L.; Liu Y.; Siddiqi F.S.; Connelly K.A.; Advani A.; Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. Cardiovasc Drugs Ther 2022,36(4),619-632","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1161\/CIRCULATIONAHA.108.837286","volume":"119","author":"Jain M.","year":"2009","unstructured":"Jain M.; Jakubowski A.; Cui L.; Shi J.; Su L.; Bauer M.; Guan J.; Lim C.C.; Naito Y.; Thompson J.S.; Sam F.; Ambrose C.; Parr M.; Crowell T.; Lincecum J.M.; Wang M.Z.; Hsu Y.M.; Zheng T.S.; Michaelson J.S.; Liao R.; Burkly L.C.; A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009,119(15),2058-2068","journal-title":"Circulation"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cyto.2013.05.009","volume":"64","author":"Novoyatleva T.","year":"2013","unstructured":"Novoyatleva T.; Janssen W.; Wietelmann A.; Schermuly R.T.; Engel F.B.; TWEAK\/Fn14 axis is a positive regulator of cardiac hypertrophy. Cytokine 2013,64(1),43-45","journal-title":"Cytokine"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00395-009-0046-y","volume":"105","author":"Chorianopoulos E.","year":"2010","unstructured":"Chorianopoulos E.; Heger T.; Lutz M.; Frank D.; Bea F.; Katus H.A.; Frey N.; FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA\/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 2010,105(2),301-313","journal-title":"Basic Res Cardiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fimmu.2014.00050","volume":"5","author":"Novoyatleva T.","year":"2014","unstructured":"Novoyatleva T.; Sajjad A.; Engel F.B.; TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. Front Immunol 2014,5,50","journal-title":"Front Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1749-6632.2012.06752.x","volume":"1269","author":"Gupta S.","year":"2012","unstructured":"Gupta S.; Kumar S.; Sopko N.; Qin Y.; Wei C.; Kim I.K.; Thymosin &#x3B2;4 and cardiac protection: Implication in inflammation and fibrosis. Ann N Y Acad Sci 2012,1269(1),84-91","journal-title":"Ann N Y Acad Sci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/676489","volume":"2013","author":"Doltra A.","year":"2013","unstructured":"Doltra A.; Stawowy P.; Dietrich T.; Schneeweis C.; Fleck E.; Kelle S.; Magnetic resonance imaging of cardiovascular fibrosis and inflammation: From clinical practice to animal studies and back. BioMed Res Int 2013,2013,1-10","journal-title":"BioMed Res Int"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","volume":"56","author":"Mel&#xE9;ndez G.C.","year":"2010","unstructured":"Mel&#xE9;ndez G.C.; Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010,56(2),225-31","journal-title":"Hypertension"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3945\/jn.108.098269","volume":"139","author":"Kennedy A.","year":"2009","unstructured":"Kennedy A.; Martinez K.; Chuang C.C.; LaPoint K.; McIntosh M.; Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: Mechanisms of action and implications. J Nutr 2009,139(1),1-4","journal-title":"J Nutr"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41419-018-0593-y","volume":"9","author":"He Y.","year":"2018","unstructured":"He Y.; Zhou L.; Fan Z.; Liu S.; Fang W.; Palmitic acid, but not high-glucose, induced myocardial apoptosis is alleviated by N-acetylcysteine due to attenuated mitochondrial-derived ROS accumulation-induced endoplasmic reticulum stress. Cell Death Dis 2018,9(5),568","journal-title":"Cell Death Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1002\/jcb.27643","volume":"120","author":"Mangali S.","year":"2019","unstructured":"Mangali S.; Bhat A.; Udumula M.P.; Dhar I.; Sriram D.; Dhar A.; Inhibition of protein kinase R protects against palmitic acid\u2013induced inflammation, oxidative stress, and apoptosis through the JNK\/NF-kB\/NLRP3 pathway in cultured H9C2 cardiomyocytes. J Cell Biochem 2019,120(3),3651-3663","journal-title":"J Cell Biochem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.119.042336","volume":"141","author":"Tang X.","year":"2020","unstructured":"Tang X.; Pan L.; Zhao S.; Dai F.; Chao M.; Jiang H.; Li X.; Lin Z.; Huang Z.; Meng G.; Wang C.; Chen C.; Liu J.; Wang X.; Ferro A.; Wang H.; Chen H.; Gao Y.; Lu Q.; Xie L.; Han Y.; Ji Y.; SNO-MLP (S-Nitrosylation of Muscle LIM Protein) Facilitates Myocardial Hypertrophy Through TLR3 (Toll-Like Receptor 3)\u2013Mediated RIP3 (Receptor-Interacting Protein Kinase 3) and NLRP3 (NOD-Like Receptor Pyrin Domain Containing 3) Inflammasome Activation. Circulation 2020,141(12),984-1000","journal-title":"Circulation"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/dom.14814","volume":"24","author":"Moellmann J.","year":"2022","unstructured":"Moellmann J.; Mann P.A.; Kappel B.A.; Kahles F.; Klinkhammer B.M.; Boor P.; Kramann R.; Ghesquiere B.; Lebherz C.; Marx N.; Lehrke M.; The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac  signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab 2022,24(11),2263-2272","journal-title":"Diabetes Obes Metab"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"Heerspink H.J.L.","year":"2019","unstructured":"Heerspink H.J.L.; Perco P.; Mulder S.; Leierer J.; Hansen M.K.; Heinzel A.; Mayer G.; Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 2019,62(7),1154-1166","journal-title":"Diabetologia"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"Andreadou I.","year":"2017","unstructured":"Andreadou I.; Efentakis P.; Balafas E.; Togliatto G.; Davos C.H.; Varela A.; Dimitriou C.A.; Nikolaou P.E.; Maratou E.; Lambadiari V.; Ikonomidis I.; Kostomitsopoulos N.; Brizzi M.F.; Dimitriadis G.; Iliodromitis E.K.; Empagliflozin Limits Myocardial Infarction in vivo and Cell Death in vitro: Role of STAT3, Mitochondria, and Redox Aspects. Front Physiol 2017,8,1077","journal-title":"Front Physiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","volume":"43","author":"Lin K.","year":"2022","unstructured":"Lin K.; Yang N.; Luo W.; Qian J.; Zhu W.; Ye S.; Yuan C.; Xu D.; Liang G.; Huang W.; Shan P.; Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling. Acta Pharmacol Sin 2022,43(10),2624-2635","journal-title":"Acta Pharmacol Sin"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Ye Y.","year":"2017","unstructured":"Ye Y.; Bajaj M.; Yang H.C.; Perez-Polo J.R.; Birnbaum Y.; SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3\/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther 2017,31(2),119-132","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"Byrne N.J.","year":"2020","unstructured":"Byrne N.J.; Matsumura N.; Maayah Z.H.; Ferdaoussi M.; Takahara S.; Darwesh A.M.; Levasseur J.L.; Jahng J.W.S.; Vos D.; Parajuli N.; El-Kadi A.O.S.; Braam B.; Young M.E.; Verma S.; Light P.E.; Sweeney G.; Seubert J.M.; Dyck J.R.B.; Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure. Circ Heart Fail 2020,13(1),e006277","journal-title":"Circ Heart Fail"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"Kim S.R.","year":"2020","unstructured":"Kim S.R.; Lee S.G.; Kim S.H.; Kim J.H.; Choi E.; Cho W.; Rim J.H.; Hwang I.; Lee C.J.; Lee M.; Oh C.M.; Jeon J.Y.; Gee H.Y.; Kim J.H.; Lee B.W.; Kang E.S.; Cha B.S.; Lee M.S.; Yu J.W.; Cho J.W.; Kim J.S.; Lee Y.; SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 2020,11(1),2127","journal-title":"Nat Commun"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/HYPERTENSIONAHA.116.07579","volume":"68","author":"Wang H.","year":"2016","unstructured":"Wang H.; CD28\/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs. Hypertension 2016,68(3),688-696","journal-title":"Hypertension"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","volume":"98","author":"Forrester S.J.","year":"2018","unstructured":"Forrester S.J.; Booz G.W.; Sigmund C.D.; Coffman T.M.; Kawai T.; Rizzo V.; Scalia R.; Eguchi S.; Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiol Rev 2018,98(3),1627-1738","journal-title":"Physiol Rev"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","volume":"65","author":"Frangogiannis N.G.","year":"2019","unstructured":"Frangogiannis N.G.; Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med 2019,65,70-99","journal-title":"Mol Aspects Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1161\/HYPERTENSIONAHA.118.11860","volume":"72","author":"Han J.","year":"2018","unstructured":"Han J.; Angiotensin II Causes Biphasic STAT3 Activation Through TLR4 to Initiate Cardiac Remodeling. Hypertension 2018,72(6),1301-1311","journal-title":"Hypertension"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"833","DOI":"10.5551\/jat.27292","volume":"22","author":"Matsuda S.","year":"2015","unstructured":"Matsuda S.; Umemoto S.; Yoshimura K.; Itoh S.; Murata T.; Fukai T.; Matsuzaki M.; Angiotensin Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4. J Atheroscler Thromb 2015,22(8),833-844","journal-title":"J Atheroscler Thromb"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"Kang S.","year":"2020","unstructured":"Kang S.; Verma S.; Hassanabad A.F.; Teng G.; Belke D.D.; Dundas J.A.; Guzzardi D.G.; Svystonyuk D.A.; Pattar S.S.; Park D.S.J.; Turnbull J.D.; Duff H.J.; Tibbles L.A.; Cunnington R.H.; Dyck J.R.B.; Fedak P.W.M.; Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol 2020,36(4),543-553","journal-title":"Can J Cardiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","volume":"20","author":"Zhang Y.","year":"2021","unstructured":"Zhang Y.; Lin X.; Chu Y.; Chen X.; Du H.; Zhang H.; Xu C.; Xie H.; Ruan Q.; Lin J.; Liu J.; Zeng J.; Ma K.; Chai D.; Dapagliflozin: A sodium\u2013glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF&#x3B2;1\/Smad signaling. Cardiovasc Diabetol 2021,20(1),121","journal-title":"Cardiovasc Diabetol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1161\/01.CIR.0000160352.58142.06","volume":"111","author":"Aoyama T.","year":"2005","unstructured":"Aoyama T.; Matsui T.; Novikov M.; Park J.; Hemmings B.; Rosenzweig A.; Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 2005,111(13),1652-1659","journal-title":"Circulation"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1096\/fj.12-218230","volume":"27","author":"Lang F.","year":"2013","unstructured":"Lang F.; Shumilina E.; Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1. FASEB J 2013,27(1),3-12","journal-title":"FASEB J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1161\/CIRCULATIONAHA.112.115592","volume":"126","author":"Das S.","year":"2012","unstructured":"Das S.; Aiba T.; Rosenberg M.; Hessler K.; Xiao C.; Quintero P.A.; Ottano F.G.; Knight A.C.; Graham E.L.; Bostr&#xF6;m P.; Morissette M.R.; del Monte F.; Begley M.J.; Cantley L.C.; Ellinor P.T.; Tomaselli G.F.; Rosenzweig A.; Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation 2012,126(18),2208-2219","journal-title":"Circulation"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"Habibi J.","year":"2017","unstructured":"Habibi J.; Aroor A.R.; Sowers J.R.; Jia G.; Hayden M.R.; Garro M.; Barron B.; Mayoux E.; Rector R.S.; Whaley-Connell A.; DeMarco V.G.; Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 2017,16(1),9","journal-title":"Cardiovasc Diabetol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/CIRCRESAHA.117.311147","volume":"122","author":"Sciarretta S.","year":"2018","unstructured":"Sciarretta S.; Forte M.; Frati G.; Sadoshima J.; New Insights Into the Role of mTOR Signaling in the Cardiovascular System. Circ Res 2018,122(3),489-505","journal-title":"Circ Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/cvr\/cvab033","volume":"118","author":"Sciarretta S.","year":"2022","unstructured":"Sciarretta S.; Forte M.; Frati G.; Sadoshima J.; The complex network of mTOR signalling in the heart. Cardiovasc Res 2022,118(2),424-439","journal-title":"Cardiovasc Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1172\/JCI25900","volume":"115","author":"O\u2019Neill B.T.","year":"2005","unstructured":"O\u2019Neill B.T.; Abel E.D.; Akt1 in the cardiovascular system: Friend or foe? J Clin Invest 2005,115(8),2059-2064","journal-title":"J Clin Invest"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dci19-0074","volume":"43","author":"Packer M.","year":"2020","unstructured":"Packer M.; SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. Diabetes Care 2020,43(3),508-511","journal-title":"Diabetes Care"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","volume":"4","author":"Osataphan S.","year":"2019","unstructured":"Osataphan S.; Macchi C.; Singhal G.; Chimene-Weiss J.; Sales V.; Kozuka C.; Dreyfuss J.M.; Pan H.; Tangcharoenpaisan Y.; Morningstar J.; Gerszten R.; Patti M.E.; SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight 2019,4(5),e123130","journal-title":"JCI Insight"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/db19-0991","volume":"69","author":"Sun X.","year":"2020","unstructured":"Sun X.; Han F.; Lu Q.; Li X.; Ren D.; Zhang J.; Han Y.; Xiang Y.K.; Li J.; Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet\u2013Induced Obese Mice. Diabetes 2020,69(6),1292-1305","journal-title":"Diabetes"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/01.CIR.103.10.1453","volume":"103","author":"Esposito G.","year":"2001","unstructured":"Esposito G.; Prasad S.V.N.; Rapacciuolo A.; Mao L.; Koch W.J.; Rockman H.A.; Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 2001,103(10),1453-1458","journal-title":"Circulation"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/ajh\/hpz016","volume":"32","author":"Shi L.","year":"2019","unstructured":"Shi L.; Zhu D.; Wang S.; Jiang A.; Li F.; Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload. Am J Hypertens 2019,32(5),452-459","journal-title":"Am J Hypertens"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","volume":"71","author":"Packer M.","year":"2018","unstructured":"Packer M.; Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol 2018,71(20),2360-2372","journal-title":"J Am Coll Cardiol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/eurheartj\/eht099","volume":"36","author":"Venteclef N.","year":"2015","unstructured":"Venteclef N.; Guglielmi V.; Balse E.; Gaborit B.; Cotillard A.; Atassi F.; Amour J.; Leprince P.; Dutour A.; Cl&#xE9;ment K.; Hatem S.N.; Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2015,36(13),795-805","journal-title":"Eur Heart J"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"e007372","DOI":"10.1161\/CIRCIMAGING.117.007372","volume":"11","author":"Ng A.C.T.","year":"2018","unstructured":"Ng A.C.T.; Strudwick M.; van der Geest R.J.; Ng A.C.C.; Gillinder L.; Goo S.Y.; Cowin G.; Delgado V.; Wang W.Y.S.; Bax J.J.; Impact of Epicardial Adipose Tissue, Left Ventricular Myocardial Fat Content, and Interstitial Fibrosis on Myocardial Contractile Function. Circ Cardiovasc Imaging 2018,11(8),e007372","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22798","volume":"28","author":"Iacobellis G.","year":"2020","unstructured":"Iacobellis G.; Gra-Menendez S.; Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. Obesity (Silver Spring) 2020,28(6),1068-1074","journal-title":"Obesity (Silver Spring)"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","volume":"9","author":"Yagi S.","year":"2017","unstructured":"Yagi S.; Hirata Y.; Ise T.; Kusunose K.; Yamada H.; Fukuda D.; Salim H.M.; Maimaituxun G.; Nishio S.; Takagawa Y.; Hama S.; Matsuura T.; Yamaguchi K.; Tobiume T.; Soeki T.; Wakatsuki T.; Aihara K.; Akaike M.; Shimabukuro M.; Sata M.; Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2017,9(1),78","journal-title":"Diabetol Metab Syndr"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s13300-017-0279-y","volume":"8","author":"Fukuda T.","year":"2017","unstructured":"Fukuda T.; Bouchi R.; Terashima M.; Sasahara Y.; Asakawa M.; Takeuchi T.; Nakano Y.; Murakami M.; Minami I.; Izumiyama H.; Hashimoto K.; Yoshimoto T.; Ogawa Y.; Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study. Diabetes Ther 2017,8(4),851-861","journal-title":"Diabetes Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","volume":"16","author":"Bouchi R.","year":"2017","unstructured":"Bouchi R.; Terashima M.; Sasahara Y.; Asakawa M.; Fukuda T.; Takeuchi T.; Nakano Y.; Murakami M.; Minami I.; Izumiyama H.; Hashimoto K.; Yoshimoto T.; Ogawa Y.; Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: A pilot study. Cardiovasc Diabetol 2017,16(1),32","journal-title":"Cardiovasc Diabetol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"Requena-Ib&#xE1;&#xF1;ez J.A.","year":"2021","unstructured":"Requena-Ib&#xE1;&#xF1;ez J.A.; Santos-Gallego C.G.; Rodriguez-Cordero A.; Vargas-Delgado A.P.; Mancini D.; Sartori S.; Atallah-Lajam F.; Giannarelli C.; Macaluso F.; Lala A.; Sanz J.; Fuster V.; Badimon J.J.; Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF. JACC Heart Fail 2021,9(8),578-589","journal-title":"JACC Heart Fail"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/cvr\/cvx186","volume":"114","author":"D&#xED;az-Rodr&#xED;guez E.","year":"2018","unstructured":"D&#xED;az-Rodr&#xED;guez E.; Agra R.M.; Fern&#xE1;ndez &#xC1;.L.; Adrio B.; Garc&#xED;a-Caballero T.; Gonz&#xE1;lez-Juanatey J.R.; Eiras S.; Effects of dapagliflozin on human epicardial adipose tissue: Modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res 2018,114(2),336-346","journal-title":"Cardiovasc Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"Sato T.","year":"2018","unstructured":"Sato T.; Aizawa Y.; Yuasa S.; Kishi S.; Fuse K.; Fujita S.; Ikeda Y.; Kitazawa H.; Takahashi M.; Sato M.; Okabe M.; The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol 2018,17(1),6","journal-title":"Cardiovasc Diabetol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cardiores.2005.11.022","volume":"69","author":"Madani S.","year":"2006","unstructured":"Madani S.; Degirolamo S.; Mu&#xF1;oz D.; Li R.; Sweeney G.; Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006,69(3),716-725","journal-title":"Cardiovasc Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.numecd.2013.11.001","volume":"24","author":"Iacobellis G.","year":"2014","unstructured":"Iacobellis G.; Diaz S.; Mendez A.; Goldberg R.; Increased epicardial fat and plasma leptin in type 1 diabetes independently of obesity. Nutr Metab Cardiovasc Dis 2014,24(7),725-729","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/01.RES.0000089255.37804.72","volume":"93","author":"Rajapurohitam V.","year":"2003","unstructured":"Rajapurohitam V.; Gan X.T.; Kirshenbaum L.A.; Karmazyn M.; The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003,93(4),277-279","journal-title":"Circ Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/01.CIR.0000140766.52771.6D","volume":"110","author":"Xu F.P.","year":"2004","unstructured":"Xu F.P.; Chen M.S.; Wang Y.Z.; Yi Q.; Lin S.B.; Chen A.F.; Luo J.D.; Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004,110(10),1269-1275","journal-title":"Circulation"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"Huby A.C.","year":"2015","unstructured":"Huby A.C.; Antonova G.; Groenendyk J.; Gomez-Sanchez C.E.; Bollag W.B.; Filosa J.A.; de Chantem&#xE8;le E.J.B.; Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation 2015,132(22),2134-2145","journal-title":"Circulation"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/dom.13229","volume":"20","author":"Packer M.","year":"2018","unstructured":"Packer M.; Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab 2018,20(6),1361-1366","journal-title":"Diabetes Obes Metab"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1097\/01.ASN.0000083903.18724.93","volume":"14","author":"Teta D.","year":"2003","unstructured":"Teta D.; Bevington A.; Brown J.; Pawluczyk I.; Harris K.; Walls J.; Acidosis downregulates leptin production from cultured adipocytes through a glucose transport-dependent post-transcriptional mechanism. J Am Soc Nephrol 2003,14(9),2248-2254","journal-title":"J Am Soc Nephrol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/jdi.13015","volume":"10","author":"Miura H.","year":"2019","unstructured":"Miura H.; Sakaguchi K.; Okada Y.; Yamada T.; Otowa-Suematsu N.; So A.; Komada H.; Hirota Y.; Ohara T.; Kuroki Y.; Hara K.; Matsuda T.; Kishi M.; Takeda A.; Yokota K.; Tamori Y.; Ogawa W.; Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study). J Diabetes Investig 2019,10(5),1254-1261","journal-title":"J Diabetes Investig"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1055\/a-0958-2441","volume":"51","author":"Wu P.","year":"2019","unstructured":"Wu P.; Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes. Horm Metab Res 2019,51(8),487-494","journal-title":"Horm Metab Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.3390\/ijms22052576","volume":"22","author":"Pruett J.E.","year":"2021","unstructured":"Pruett J.E.; Torres Fernandez E.D.; Everman S.J.; Vinson R.M.; Davenport K.; Logan M.K.; Ye S.A.; Romero D.G.; Yanes Cardozo L.L.; Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. Int J Mol Sci 2021,22(5),2576","journal-title":"Int J Mol Sci"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cvr\/cvr015","volume":"90","author":"Abel E.D.","year":"2011","unstructured":"Abel E.D.; Doenst T.; Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 2011,90(2),234-242","journal-title":"Cardiovasc Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cvr\/cvq240","volume":"88","author":"Rosca M.G.","year":"2010","unstructured":"Rosca M.G.; Hoppel C.L.; Mitochondria in heart failure. Cardiovasc Res 2010,88(1),40-50","journal-title":"Cardiovasc Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1006\/jmcc.2001.1378","volume":"33","author":"Lesnefsky E.J.","year":"2001","unstructured":"Lesnefsky E.J.; Moghaddas S.; Tandler B.; Kerner J.; Hoppel C.L.; Mitochondrial dysfunction in cardiac disease: Ischemia--reperfusion, aging, and heart failure. J Mol Cell Cardiol 2001,33(6),1065-1089","journal-title":"J Mol Cell Cardiol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1122494","volume":"2022","author":"Wang J.","year":"2022","unstructured":"Wang J.; Huang X.; Liu H.; Chen Y.; Li P.; Liu L.; Li J.; Ren Y.; Huang J.; Xiong E.; Tian Z.; Dai X.; Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function. Oxid Med Cell Longev 2022,2022,1-16","journal-title":"Oxid Med Cell Longev"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/cvr\/cvx149","volume":"114","author":"Bertero E.","year":"2018","unstructured":"Bertero E.; Prates Roma L.; Ameri P.; Maack C.; Cardiac effects of SGLT2 inhibitors: The sodium hypothesis. Cardiovasc Res 2018,114(1),12-18","journal-title":"Cardiovasc Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"Baartscheer A.","year":"2017","unstructured":"Baartscheer A.; Schumacher C.A.; W&#xFC;st R.C.I.; Fiolet J.W.T.; Stienen G.J.M.; Coronel R.; Zuurbier C.J.; Empagliflozin decreases myocardial cytoplasmic Na through inhibition of the cardiac Na\/H exchanger in rats and rabbits. Diabetologia 2017,60(3),568-573","journal-title":"Diabetologia"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCRESAHA.118.310082","volume":"122","author":"Bertero E.","year":"2018","unstructured":"Bertero E.; Maack C.; Calcium Signaling and Reactive Oxygen Species in Mitochondria. Circ Res 2018,122(10),1460-1478","journal-title":"Circ Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"Zhou H.","year":"2018","unstructured":"Zhou H.; Wang S.; Zhu P.; Hu S.; Chen Y.; Ren J.; Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 2018,15,335-346","journal-title":"Redox Biol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"Tanajak P.","year":"2018","unstructured":"Tanajak P.; Sa-nguanmoo P.; Sivasinprasasn S.; Thummasorn S.; Siri-Angkul N.; Chattipakorn S.C.; Chattipakorn N.; Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol 2018,236(2),69-84","journal-title":"J Endocrinol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Shao Q.","year":"2019","unstructured":"Shao Q.; Meng L.; Lee S.; Tse G.; Gong M.; Zhang Z.; Zhao J.; Zhao Y.; Li G.; Liu T.; Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol 2019,18(1),165","journal-title":"Cardiovasc Diabetol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.yjmcc.2013.02.007","volume":"61","author":"Wakabayashi S.","year":"2013","unstructured":"Wakabayashi S.; Hisamitsu T.; Nakamura T.Y.; Regulation of the cardiac Na+\/H+ exchanger in health and disease. J Mol Cell Cardiol 2013,61,68-76","journal-title":"J Mol Cell Cardiol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1152\/physiolgenomics.00064.2010","volume":"42","author":"Xue J.","year":"2010","unstructured":"Xue J.; Mraiche F.; Zhou D.; Karmazyn M.; Oka T.; Fliegel L.; Haddad G.G.; Elevated myocardial Na  \/H  exchanger isoform 1 activity elicits gene expression that leads to cardiac hypertrophy. Physiol Genomics 2010,42(3),374-383","journal-title":"Physiol Genomics"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.hipert.2019.09.002","volume":"37","author":"Yeves A.M.","year":"2020","unstructured":"Yeves A.M.; Ennis I.L.; Na\/H exchanger and cardiac hypertrophy. Hipertens Riesgo Vasc 2020,37(1),22-32","journal-title":"Hipertens Riesgo Vasc"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2840-11-33","volume":"11","author":"Anzawa R.","year":"2012","unstructured":"Anzawa R.; Seki S.; Nagoshi T.; Taniguchi I.; Feuvray D.; Yoshimura M.; The role of Na+\/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db\/db mice. Cardiovasc Diabetol 2012,11(1),33","journal-title":"Cardiovasc Diabetol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00125-007-0628-x","volume":"50","author":"Darmellah A.","year":"2007","unstructured":"Darmellah A.; Baetz D.; Prunier F.; Tamareille S.; R&#xFC;cker-Martin C.; Feuvray D.; Enhanced activity of the myocardial Na+\/H+ exchanger contributes to left ventricular hypertrophy in the Goto\u2013Kakizaki rat model of type 2 diabetes: Critical role of Akt. Diabetologia 2007,50(6),1335-1344","journal-title":"Diabetologia"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","volume":"103","author":"Nakamura T.Y.","year":"2008","unstructured":"Nakamura T.Y.; Iwata Y.; Arai Y.; Komamura K.; Wakabayashi S.; Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 2008,103(8),891-899","journal-title":"Circ Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s11010-022-04411-6","volume":"477","author":"Abdulrahman N.","year":"2022","unstructured":"Abdulrahman N.; Ibrahim M.; Joseph J.M.; Elkoubatry H.M.; Al-Shamasi A.A.; Rayan M.; Gadeau A.P.; Ahmed R.; Eldassouki H.; Hasan A.; Mraiche F.; Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression. Mol Cell Biochem 2022,477(6),1865-1872","journal-title":"Mol Cell Biochem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/hr.2011.196","volume":"35","author":"Watkins S.J.","year":"2012","unstructured":"Watkins S.J.; Borthwick G.M.; Oakenfull R.; Robson A.; Arthur H.M.; Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2\/3-independent. Hypertens Res 2012,35(4),393-398","journal-title":"Hypertens Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"e0122230","DOI":"10.1371\/journal.pone.0122230","volume":"10","author":"Jaballah M.","year":"2015","unstructured":"Jaballah M.; Mohamed I.A.; Alemrayat B.; Al-Sulaiti F.; Mlih M.; Mraiche F.; Na+\/H+ exchanger isoform 1 induced cardiomyocyte hypertrophy involves activation of p90 ribosomal s6 kinase. PLoS One 2015,10(4),e0122230","journal-title":"PLoS One"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardiores.2004.09.024","volume":"65","author":"Baartscheer A.","year":"2005","unstructured":"Baartscheer A.; Schumacher C.; Vanborren M.; Belterman C.; Coronel R.; Opthof T.; Fiolet J.; Chronic inhibition of Na\/H-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res 2005,65(1),83-92","journal-title":"Cardiovasc Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"H738","DOI":"10.1152\/ajpheart.2001.280.2.H738","volume":"280","author":"Kusumoto K.","year":"2001","unstructured":"Kusumoto K.; Haist J.V.; Karmazyn M.; Na  \/H  exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2001,280(2),H738-H745","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"Uthman L.","year":"2018","unstructured":"Uthman L.; Baartscheer A.; Bleijlevens B.; Schumacher C.A.; Fiolet J.W.T.; Koeman A.; Jancev M.; Hollmann M.W.; Weber N.C.; Coronel R.; Zuurbier C.J.; Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na\/H exchanger, lowering of cytosolic Na and vasodilation. Diabetologia 2018,61(3),722-726","journal-title":"Diabetologia"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"Spigoni V.","year":"2020","unstructured":"Spigoni V.; Fantuzzi F.; Carubbi C.; Pozzi G.; Masselli E.; Gobbi G.; Solini A.; Bonadonna R.C.; Dei Cas A.; Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: Potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol 2020,19(1),46","journal-title":"Cardiovasc Diabetol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","volume":"109","author":"Yang C.-C.","year":"2019","unstructured":"Yang C.-C.; Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomed Pharmacother 2019,109(8),658-670","journal-title":"Biomed Pharmacother"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"Ye Y.","year":"2018","unstructured":"Ye Y.; Jia X.; Bajaj M.; Birnbaum Y.; Dapagliflozin Attenuates Na\/H Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovasc Drugs Ther 2018,32(6),553-558","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"7642","DOI":"10.1111\/jcmm.16601","volume":"25","author":"Tian J.","year":"2021","unstructured":"Tian J.; Zhang M.; Suo M.; Liu D.; Wang X.; Liu M.; Pan J.; Jin T.; An F.; Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK&#x3B1;\/TGF-&#x3B2;\/Smad signalling in type 2 diabetic rats. J Cell Mol Med 2021,25(16),7642-7659","journal-title":"J Cell Mol Med"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"14659","DOI":"10.1038\/s41598-020-71599-2","volume":"10","author":"Hasan R.","year":"2020","unstructured":"Hasan R.; Lasker S.; Hasan A.; Zerin F.; Zamila M.; Parvez F.; Rahman M.M.; Khan F.; Subhan N.; Alam M.A.; Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK\u2013Akt\u2013eNOS pathway in the isoprenaline-induced oxidative stress model. Sci Rep 2020,10(1),14659","journal-title":"Sci Rep"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0008-6363(98)00233-8","volume":"42","author":"Paternostro G.","year":"1999","unstructured":"Paternostro G.; Pagano D.; Gnecchi-Ruscone T.; Bonser R.S.; Camici P.G.; Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999,42(1),246-253","journal-title":"Cardiovasc Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"Jia G.","year":"2018","unstructured":"Jia G.; Hill M.A.; Sowers J.R.; Diabetic Cardiomyopathy. Circ Res 2018,122(4),624-638","journal-title":"Circ Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"R1481","DOI":"10.1152\/ajpregu.00232.2003","volume":"285","author":"Sundgren N.C.","year":"2003","unstructured":"Sundgren N.C.; Giraud G.D.; Schultz J.M.; Lasarev M.R.; Stork P.J.S.; Thornburg K.L.; Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes. Am J Physiol Regul Integr Comp Physiol 2003,285(6),R1481-R1489","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"Ferrannini E.","year":"2014","unstructured":"Ferrannini E.; Muscelli E.; Frascerra S.; Baldi S.; Mari A.; Heise T.; Broedl U.C.; Woerle H.J.; Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014,124(2),499-508","journal-title":"J Clin Invest"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/dia.2013.0167","volume":"16","author":"Mudaliar S.","year":"2014","unstructured":"Mudaliar S.; Henry R.R.; Boden G.; Smith S.; Chalamandaris A.G.; Duchesne D.; Iqbal N.; List J.; Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014,16(3),137-144","journal-title":"Diabetes Technol Ther"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","volume":"40","author":"Scheen A.J.","year":"2014","unstructured":"Scheen A.J.; Paquot N.; Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab 2014,40(6)(Suppl. 1),S4-S11","journal-title":"Diabetes Metab"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"Hammoudi N.","year":"2017","unstructured":"Hammoudi N.; Jeong D.; Singh R.; Farhat A.; Komajda M.; Mayoux E.; Hajjar R.; Lebeche D.; Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. Cardiovasc Drugs Ther 2017,31(3),233-246","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.jacc.2014.02.572","volume":"63","author":"Murdoch C.E.","year":"2014","unstructured":"Murdoch C.E.; Chaubey S.; Zeng L.; Yu B.; Ivetic A.; Walker S.J.; Vanhoutte D.; Heymans S.; Grieve D.J.; Cave A.C.; Brewer A.C.; Zhang M.; Shah A.M.; Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 2014,63(24),2734-2741","journal-title":"J Am Coll Cardiol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","volume":"4","author":"Juni R.P.","year":"2019","unstructured":"Juni R.P.; Kuster D.W.D.; Goebel M.; Helmes M.; Musters R.J.P.; van der Velden J.; Koolwijk P.; Paulus W.J.; van Hinsbergh V.W.M.; Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC Basic Transl Sci 2019,4(5),575-591","journal-title":"JACC Basic Transl Sci"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.5551\/jat.52100","volume":"27","author":"Rahadian A.","year":"2020","unstructured":"Rahadian A.; Fukuda D.; Salim H.M.; Yagi S.; Kusunose K.; Yamada H.; Soeki T.; Sata M.; Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice. J Atheroscler Thromb 2020,27(11),1141-1151","journal-title":"J Atheroscler Thromb"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"Pabel S.","year":"2018","unstructured":"Pabel S.; Wagner S.; Bollenberg H.; Bengel P.; Kov&#xE1;cs &#xC1;.; Schach C.; Tirilomis P.; Mustroph J.; Renner A.; Gummert J.; Fischer T.; Van Linthout S.; Tsch&#xF6;pe C.; Streckfuss-B&#xF6;meke K.; Hasenfuss G.; Maier L.S.; Hamdani N.; Sossalla S.; Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail 2018,20(12),1690-1700","journal-title":"Eur J Heart Fail"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","volume":"3","author":"Salim H.M.","year":"2016","unstructured":"Salim H.M.; Fukuda D.; Yagi S.; Soeki T.; Shimabukuro M.; Sata M.; Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Front Cardiovasc Med 2016,3,43","journal-title":"Front Cardiovasc Med"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","volume":"17","author":"Lee D.M.","year":"2018","unstructured":"Lee D.M.; Battson M.L.; Jarrell D.K.; Hou S.; Ecton K.E.; Weir T.L.; Gentile C.L.; SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol 2018,17(1),62","journal-title":"Cardiovasc Diabetol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1172\/JCI73938","volume":"125","author":"Levine B.","year":"2015","unstructured":"Levine B.; Packer M.; Codogno P.; Development of autophagy inducers in clinical medicine. J Clin Invest 2015,125(1),14-24","journal-title":"J Clin Invest"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","volume":"176","author":"Levine B.","year":"2019","unstructured":"Levine B.; Kroemer G.; Biological Functions of Autophagy Genes: A Disease Perspective. Cell 2019,176(1-2),11-42","journal-title":"Cell"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"328","DOI":"10.4161\/auto.22971","volume":"9","author":"Dutta D.","year":"2013","unstructured":"Dutta D.; Xu J.; Kim J.S.; Dunn W.A.; Leeuwenburgh C.; Upregulated autophagy protects cardiomyocytes from oxidative stress-induced toxicity. Autophagy 2013,9(3),328-344","journal-title":"Autophagy"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1093\/eurheartj\/ehaa360","volume":"41","author":"Packer M.","year":"2020","unstructured":"Packer M.; Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: Implications for understanding the effects of current and future treatments for heart failure. Eur Heart J 2020,41(39),3856-3861","journal-title":"Eur Heart J"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/01.RES.0000267723.65696.4a","volume":"100","author":"Alcendor R.R.","year":"2007","unstructured":"Alcendor R.R.; Gao S.; Zhai P.; Zablocki D.; Holle E.; Yu X.; Tian B.; Wagner T.; Vatner S.F.; Sadoshima J.; Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007,100(10),1512-1521","journal-title":"Circ Res"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1074\/jbc.M109.090266","volume":"285","author":"Tanno M.","year":"2010","unstructured":"Tanno M.; Kuno A.; Yano T.; Miura T.; Hisahara S.; Ishikawa S.; Shimamoto K.; Horio Y.; Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 2010,285(11),8375-8382","journal-title":"J Biol Chem"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4602715","volume":"2017","author":"Ma S.","year":"2017","unstructured":"Ma S.; Feng J.; Zhang R.; Chen J.; Han D.; Li X.; Yang B.; Li X.; Fan M.; Li C.; Tian Z.; Wang Y.; Cao F.; SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice. Oxid Med Cell Longev 2017,2017,1-15","journal-title":"Oxid Med Cell Longev"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/cvr\/cvy131","volume":"114","author":"Bugyei-Twum A.","year":"2018","unstructured":"Bugyei-Twum A.; Ford C.; Civitarese R.; Seegobin J.; Advani S.L.; Desjardins J.F.; Kabir G.; Zhang Y.; Mitchell M.; Switzer J.; Thai K.; Shen V.; Abadeh A.; Singh K.K.; Billia F.; Advani A.; Gilbert R.E.; Connelly K.A.; Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2\/3 transactivation. Cardiovasc Res 2018,114(12),1629-1641","journal-title":"Cardiovasc Res"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","volume":"13","author":"Packer M.","year":"2020","unstructured":"Packer M.; Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors. Circ Heart Fail 2020,13(9),e007197","journal-title":"Circ Heart Fail"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1080\/15548627.2015.1051295","volume":"11","author":"Kanamori H.","year":"2015","unstructured":"Kanamori H.; Takemura G.; Goto K.; Tsujimoto A.; Mikami A.; Ogiviano A.; Watanabe T.; Morishita K.; Okada H.; Kawasaki M.; Seishima M.; Minatoguchi S.; Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes. Autophagy 2015,11(7),1146-1160","journal-title":"Autophagy"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.molcel.2018.10.007","volume":"72","author":"Krzysiak T.C.","year":"2018","unstructured":"Krzysiak T.C.; Thomas L.; Choi Y.J.; Auclair S.; Qian Y.; Luan S.; Krasnow S.M.; Thomas L.L.; Koharudin L.M.I.; Benos P.V.; Marks D.L.; Gronenborn A.M.; Thomas G.; An Insulin-Responsive Sensor in the SIRT1 Disordered Region Binds DBC1 and PACS-2 to Control Enzyme Activity. Mol Cell 2018,72(6),985-998.e7","journal-title":"Mol Cell"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1055\/s-0033-1347209","volume":"45","author":"Paula-Gomes S.","year":"2013","unstructured":"Paula-Gomes S.; nsulin suppresses atrophy- and autophagy-related genes in heart tissue and cardiomyocytes through AKT\/FOXO signaling. Horm Metab Res 2013,45(12),849-55","journal-title":"Horm Metab Res"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"101338","DOI":"10.1016\/j.arr.2021.101338","volume":"68","author":"Dewanjee S.","year":"2021","unstructured":"Dewanjee S.; Vallamkondu J.; Kalra R.S.; John A.; Reddy P.H.; Kandimalla R.; Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Res Rev 2021,68,101338","journal-title":"Ageing Res Rev"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-020-01041-4","volume":"19","author":"Packer M.","year":"2020","unstructured":"Packer M.; Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovasc Diabetol 2020,19(1),62","journal-title":"Cardiovasc Diabetol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ejhf.1732","volume":"22","author":"Packer M.","year":"2020","unstructured":"Packer M.; Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium\u2013glucose cotransporter 2 inhibitors. Eur J Heart Fail 2020,22(4),618-628","journal-title":"Eur J Heart Fail"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","volume":"8","author":"Umino H.","year":"2018","unstructured":"Umino H.; Hasegawa K.; Minakuchi H.; Muraoka H.; Kawaguchi T.; Kanda T.; Tokuyama H.; Wakino S.; Itoh H.; High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection. Sci Rep 2018,8(1),6791","journal-title":"Sci Rep"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1042\/CS20190863","volume":"133","author":"Swe M.T.","year":"2019","unstructured":"Swe M.T.; Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clin Sci 2019,133(23),2415-2430","journal-title":"Clin Sci"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2337\/db16-1602","volume":"66","author":"Sasaki M.","year":"2017","unstructured":"Sasaki M.; Sasako T.; Kubota N.; Sakurai Y.; Takamoto I.; Kubota T.; Inagi R.; Seki G.; Goto M.; Ueki K.; Nangaku M.; Jomori T.; Kadowaki T.; Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. Diabetes 2017,66(9),2339-2350","journal-title":"Diabetes"},{"key":"ref=161","author":"Kim J-W.","year":"2018","unstructured":"Kim J-W.; Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and &#x3B1;-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem 2018","journal-title":"J Cell Biochem"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.18632\/aging.101954","volume":"11","author":"Ying Y.","year":"2019","unstructured":"Ying Y.; Jiang C.; Zhang M.; Jin J.; Ge S.; Wang X.; Phloretin protects against cardiac damage and remodeling via restoring SIRT1 and anti-inflammatory effects in the streptozotocin-induced diabetic mouse model. Aging (Albany NY) 2019,11(9),2822-2835","journal-title":"Aging (Albany NY)"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"921","DOI":"10.4093\/dmj.2020.0187","volume":"45","author":"Lee J.Y.","year":"2021","unstructured":"Lee J.Y.; Lee M.; Lee J.Y.; Bae J.; Shin E.; Lee Y.; Lee B.W.; Kang E.S.; Cha B.S.; Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK\/ SIRT1 Pathway. Diabetes Metab J 2021,45(6),921-932","journal-title":"Diabetes Metab J"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4254\/wjh.v12.i7.350","volume":"12","author":"Suga T.","year":"2020","unstructured":"Suga T.; Sato K.; Ohyama T.; Matsui S.; Kobayashi T.; Tojima H.; Horiguchi N.; Yamazaki Y.; Kakizaki S.; Nishikido A.; Okamura T.; Yamada M.; Kitamura T.; Uraoka T.; Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. World J Hepatol 2020,12(7),350-362","journal-title":"World J Hepatol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","volume":"65","author":"Hawley S.A.","year":"2016","unstructured":"Hawley S.A.; Ford R.J.; Smith B.K.; Gowans G.J.; Mancini S.J.; Pitt R.D.; Day E.A.; Salt I.P.; Steinberg G.R.; Hardie D.G.; The Na+\/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels. Diabetes 2016,65(9),2784-2794","journal-title":"Diabetes"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","volume":"8","author":"Mancini S.J.","year":"2018","unstructured":"Mancini S.J.; Boyd D.; Katwan O.J.; Strembitska A.; Almabrouk T.A.; Kennedy S.; Palmer T.M.; Salt I.P.; Canagliflozin inhibits interleukin-1&#x3B2;-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep 2018,8(1),5276","journal-title":"Sci Rep"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","volume":"170","author":"Arag&#xF3;n-Herrera A.","year":"2019","unstructured":"Arag&#xF3;n-Herrera A.; Feij&#xF3;o-Band&#xED;n S.; Otero Santiago M.; Barral L.; Campos-Toimil M.; Gil-Longo J.; Costa Pereira T.M.; Garc&#xED;a-Caballero T.; Rodr&#xED;guez-Segade S.; Rodr&#xED;guez J.; Taraz&#xF3;n E.; Rosell&#xF3;-Llet&#xED; E.; Portol&#xE9;s M.; Gualillo O.; Gonz&#xE1;lez-Juanatey J.R.; Lago F.; Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol 2019,170,113677","journal-title":"Biochem Pharmacol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"e13741","DOI":"10.14814\/phy2.13741","volume":"6","author":"Mizuno M.","year":"2018","unstructured":"Mizuno M.; Kuno A.; Yano T.; Miki T.; Oshima H.; Sato T.; Nakata K.; Kimura Y.; Tanno M.; Miura T.; Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep 2018,6(12),e13741","journal-title":"Physiol Rep"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","volume":"152","author":"Xu C.","year":"2018","unstructured":"Xu C.; Wang W.; Zhong J.; Lei F.; Xu N.; Zhang Y.; Xie W.; Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol 2018,152,45-59","journal-title":"Biochem Pharmacol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","volume":"317","author":"Lee Y.H.","year":"2019","unstructured":"Lee Y.H.; Kim S.H.; Kang J.M.; Heo J.H.; Kim D.J.; Park S.H.; Sung M.; Kim J.; Oh J.; Yang D.H.; Lee S.H.; Lee S.Y.; Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol 2019,317(4),F767-F780","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"Adingupu D.D.","year":"2019","unstructured":"Adingupu D.D.; G&#xF6;pel S.O.; Gr&#xF6;nros J.; Behrendt M.; Sotak M.; Miliotis T.; Dahlqvist U.; Gan L.M.; J&#xF6;nsson-Rylander A.C.; SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob mice. Cardiovasc Diabetol 2019,18(1),16","journal-title":"Cardiovasc Diabetol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrm3495","volume":"14","author":"Maillet M.","year":"2013","unstructured":"Maillet M.; van Berlo J.H.; Molkentin J.D.; Molecular basis of physiological heart growth: Fundamental concepts and new players. Nat Rev Mol Cell Biol 2013,14(1),38-48","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666230907115831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220801\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450124666230907115831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T15:34:06Z","timestamp":1704900846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220801\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":172,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450124666230907115831","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}